title: Piperacillin/Tazobactam - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 476/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Piperacillin/Tazobactam
  Revision Date : 16-11-2020
  |
  Approved: TC, KOH
  |
  Alert
  |
  The Antimicrobial Stewardship Team has listed this drug under the following categories:
  Restricted.
  |
  Indication
  |
  Therapy of non-CNS systemic infections, necrotising enterocolitis and intra-abdominal infections caused by susceptible Gram positive and Gram negative bacteria including anaerobes and many Enterobacterales and Pseudomonas spp.(1)
  Susceptibility of coagulase-negative staphylococci (CONS) is generally not tested though oxacillin-resistant CONS should be considered resistant and piperacillin-tazobactam should not be used as first-line for suspected CONS sepsis.(2)
  |
  Action
  |
  β-lactam/β-lactamase inhibitor combination with a broad spectrum of antibacterial activity encompassing Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria, including many pathogens producing β-lactamases.(1) Piperacillin component is a semi synthetic penicillin that inhibits septum and cell wall synthesis of susceptible bacteria. Tazobactam is a beta lactamase inhibitor that enhances the antibiotic spectrum of piperacillin.
  |
  Drug type
  |
  Antibiotic – ureidopenicillin and beta-lactamase inhibitor.
  |
  Trade name
  |
  Piperacillin/Tazobactam Kabi, Tazocin EF, PiperTaz, Piptaz, PipTaz-AFT, Tazopip
  |
  Presentation
  |
  4.5 g vial (4 g piperacillin and 0.5 g tazobactam).
  |
  Dose
  |
  Dose based on piperacillin component (3, 4)
  |
  |
  | |